Discover what's new in topical drugs

Article

The key to treating any disease is to know your enemy before engaging in the battle.

Key Points

The key to treating any disease is to know your enemy before engaging in the battle. Even with the evolved understanding in the ophthalmic industry, ocular pathogens adapt quickly to the numerous efforts to fight them. Thus, the anti-infective and anti-inflammatory methods of treatment are constantly challenged to keep pace.

New drug classes, synthetic non-antibiotic anti-infectives, and combination drugs provide the topical anti-infective and anti-inflammatory pipeline with many possibilities for treating diseases in ways that were previously impossible.

Anti-infective formulations

Another promising ophthalmic compound is FST-100 (Foresight Biotherapeutics), a combination povidone-iodine and dexamethasone ophthalmic suspension that targets the dual clinical needs of microbial eradication and reduction in inflammation associated with ocular infections.

FST-100 is currently in development for the treatment of adenoviral conjunctivitis.1 Povidone-iodine (PVP-I) is a well-characterized broad-spectrum antiseptic that works by iodination of lipids and oxidation of cytoplasmic and membrane compounds and may provide antimicrobial activity with no known risk of microbial resistance. One pilot study concluded that FST-100 showed efficacy in reducing both the inflammatory and infectious components in patients who tested positive for adenoviral antigen.2

One drug advancing in the pipeline of therapeutics for local delivery in ocular disease is ESBA105 (ESBATech). ESBA105 is a single-chain antibody fragment directed against TNF-alpha, a major mediator of inflammation.3 ESBATech has initiated a phase IIa study in patients with acute anterior uveitis4 and a phase Ib/IIa study in patients undergoing cataract surgery.5 Preclinical studies have shown that topically administered ESBA105 reaches therapeutic levels in the anterior and posterior segment and shows potential for clinical use to treat TNF-alpha dependant diseases of the eye.6

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
Christi Closson, OD, FAAO, shares her excitement for the new Acuvue Oasys MAX 1-Day multifocal for astigmatism
Karen R. Hoffman, OD, shares how customizable scleral lenses can transform vision for patients with complex corneas, achieving 20/20 outcomes and enhanced comfort.
Janna Pham, OD, shares key takeaways from a corneal tomography session she presented alongside Travis Pfeifer, OD, and Matthew McGee, OD.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
When Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, began fitting scleral lenses 20 years ago, there was limited knowledge about conjunctival characteristics, scleral shape, and lens behavior.
Ioussifova details what sets Johnson & Johnson's new lens apart from the rest, which was launched at the American Optometric Association's Optometry's Meeting 2025.
Alongside Rachel Steele, OD, Rafieetary outlines what to look for in blurred disc margins and the importance of acting fast and sending patients to the ED when needed.
Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, emphasized that every staff member should play a role in myopia management during his presentation at Optometry's Meeting 2025.
Dr Ashley Tucker Wallace discusses the intersection of pediatric dry eye and myopia control
© 2025 MJH Life Sciences

All rights reserved.